癌症中调节性细胞死亡方式的研究进展与未来展望  

Progress and prospects:regulated cell death in cancer

作　　者：龚琳婧 石毓君[1] GONG Linjing;SHI Yujun(Institute of Clinical Pathology,Key Laboratory of Transplant Engineering and Immunology,NHC,West China Hospital,Sichuan University,Chengdu 610041,P.R.China;Department of Respiratory and Critical Care Medicine,West China Hospital,Sichuan University,Chengdu 610041,P.R.China)

机构地区：[1]四川大学华西医院临床病理研究所卫健委移植工程与移植免疫重点实验室,成都610041 [2]四川大学华西医院呼吸与危重症医学科,成都610041

出　　处：《中国普外基础与临床杂志》2022年第5期582-584,共3页Chinese Journal of Bases and Clinics In General Surgery

基　　金：国家自然科学基金(项目编号:82072689)。

摘　　要：癌症是一种以细胞死亡失调为特征的异质性疾病。细胞死亡最初主要分为意外性细胞死亡和调节性细胞死亡(regulated cell death,RCD)。目前,研究者已经发现了数十种RCD方式,其中细胞凋亡、细胞焦亡、坏死性凋亡和铁死亡是近年来研究得最为广泛的4种形式。铜死亡是2022年3月17日最新提出的一种铜和线粒体依赖的独立的细胞死亡机制。针对调节不同细胞死亡途径的靶向药物的研发将是未来难治性癌症治疗的热点和难点。Cancer is a heterogeneous disease characterized by maladjustment of cell death.The types of cell death were mainly divided into two forms including accidental cell death and regulated cell death(RCD).In recent years,researchers have discovered dozens of RCD modes,among which apoptosis,pyroptosis,necroptosis,and ferroptosis are the most widely studied.Cuproptosis is a new cell death mechanism that first proposed on 17 March 2022.It is recognized as a unique and both copper and mitochondria dependent RCD.The research and development of targeted drugs for regulating different cell death pathways will be hots and difficulties in the treatment of refractory cancer in the future.

关 键 词：癌症 调节性细胞死亡 发病机制 治疗 

分 类 号：R730.5[医药卫生—肿瘤]